| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963068 | Vaccine | 2016 | 9 Pages |
Abstract
Taken together, the data show that G103 is a viable candidate for development of a novel prophylactic and therapeutic HSV-2 vaccine.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jared M. Odegard, Patrick A. Flynn, David J. Campbell, Scott H. Robbins, Lichun Dong, Kening Wang, Jan ter Meulen, Jeffrey I. Cohen, David M. Koelle,